Multiple Sclerosis International / 2015 / Article / Tab 1

Research Article

Fingolimod Treatment in Relapsing-Remitting Multiple Sclerosis Patients: A Prospective Observational Multicenter Postmarketing Study

Table 1

Patient demographics and baseline clinical characteristics.

Total ()Men ()Women () value

Age (y)39.56 ± 9.1139.63 ± 8.1539.53 ± 9.590.954
Duration of disease (y)11.37 ± 6.7411.01 ± 6.1310.62 ± 7.440.759
Number of previous DMT1.51 ± 0.831.47 ± 0.801.54 ± 0.850.644
Duration of DMT (months)59.52 ± 45.4932.02 ± 46.4558.28 ± 45.210.647
Previous immunosuppressant therapy19.01%25.53%15.78%0.164
Previous use of natalizumab19.71%12.76%23.15%0.143

In the year prior to commencing fingolimod

EDSS score2.52 ± 1.022.36 ± 1.022.60 ± 1.080.222
ARR1.14 ± 0.711.06 ± 0.601.18 ± 0.780.373
New or newly enlarging T2 lesions72.3%70.2%73.4%0.690
Gadolinium enhancing lesions49.6%44.7%52.1%0.404

Data are mean ± SD unless otherwise indicated.
ARR: annualized relapse rate.
DMT: disease modifying therapy.
EDSS: Expanded Disability Status Scale.

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.